Breaking news on headache and migraine
ROXRO PHARMA Announces Positive Clinical Proof Of Concept Results For Novel Intranasal Migraine Treatment published
Tue, 29 Apr 2008 00:00:00 PDT
ROXRO PHARMA, Inc. announced positive top-line data from a clinical study of the company's novel investigational intranasal pain reliever in the treatment of migraine and related symptoms. The placebo-controlled proof of concept study evaluated the efficacy and safety of ROX-828, an intranasal formulation of the non-steroidal anti-inflammatory (NSAID) pain reliever ketorolac.
Sensitive Skin A Symptom Of Migraine published
Wed, 23 Apr 2008 05:00:00 PDT
"Migraine hurts skin" is the headline in the Daily Mirror. The newspaper describes the symptom of sensitive skin, called allodynia, where sufferers of migraine find combing their hair, wearing jewellery or getting dressed "excruciatingly painful". The newspaper reports that 10% of people in the UK suffer migraine. The Daily Telegraph covers the same story and suggests "two thirds of migraine sufferers reported symptoms of the condition allodynia".
Migraine Increases Risk Of Severe Skin Sensitivity And Pain published
Tue, 22 Apr 2008 00:00:00 PDT
People with migraine are more likely to experience exacerbated skin sensitivity or pain after non-painful daily activities such as rubbing one's head, combing one's hair and wearing necklaces or earrings, compared to people with other types of headache, according to a study published in the April 22, 2008, issue of Neurology®, the medical journal of the American Academy of Neurology.
Teva Announces Tentative Approval Of Generic Maxalt(R) Tablets published
Mon, 21 Apr 2008 01:00:00 PDT
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Merck's migraine pain treatment Maxalt® (Rizatriptan Benzoate) Tablets, equivalent to 5 mg and 10 mg base. Final approval of this product is anticipated upon expiration of patent protection for the brand product in June 2012.
Treximet (sumatriptan And Naproxen Sodium) Tablets Approved By FDA For Acute Treatment Of Migraine published
Mon, 21 Apr 2008 00:00:00 PDT
GlaxoSmithKline (LSE & NYSE: GSK) and POZEN Inc. (NASDAQ: POZN) announced that the FDA has approved Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines pioneered by GSK, and an anti-inflammatory pain reliever in a single tablet.
Concentrating On Different Aspects Of Pain Leads To Breakthrough In Migraine Genetics published
Mon, 21 Apr 2008 00:00:00 PDT
In a new study, published in the American Journal of Human Genetics, researchers were able for the first time to convincingly demonstrate a genomic locus to be linked to migraine susceptibility in two diverse populations. Migraine is the most common cause of episodic headache, and by far the most common neurological cause of a doctor's visit.
Overuse Of Codeine, Oxycodone And Barbiturates Increases Risk Of Chronic Migraine published
Sun, 20 Apr 2008 00:00:00 PDT
People who overuse barbiturates and opioids, such as codeine, butalbital, and oxycodone, to treat migraine are at an increased risk of developing chronic migraine, according to research that will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12 - 19, 2008.People with chronic migraine have headaches on 15 or more days a month.
Children With Migraine At Increased Risk Of Sleep Disturbances published
Sun, 20 Apr 2008 00:00:00 PDT
Children with migraine are more likely to have sleep disorders, such as sleep apnea and lack of sleep, than children without migraine, according to research on the effects of headaches on children's sleep patterns that will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12 - 19, 2008.
Migraine Frequency Linked With Women's Risk Of Cardiovascular Disease published
Sun, 20 Apr 2008 00:00:00 PDT
New research shows women who have weekly migraine are significantly more likely to have a stroke than those with fewer migraines or no migraine at all, but those with lower migraine frequency may face increased risk of heart attacks. The research will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12 - 19, 2008.The Women's Health Study involved 27,798 women health professionals in the United States who were 45 and older.
Breakthrough In Migraine Genetics published
Fri, 18 Apr 2008 05:00:00 PDT
Migraine is the most common cause of episodic headache, and by far the most common neurological cause of a doctor's visit. It affects some 15% of the population, including some 41 million people in Europe, and places a considerable burden on healthcare in both the developed and the developing world.
A Wild Plant Growing In The Mediterranean Provides Anticancer Medicines published
Fri, 18 Apr 2008 05:00:00 PDT
A group of scientists from the Department of Organic Chemistry and the Biotechnology Institute of the University of Granada have found that the plant "Dittirichia viscose", known as elecampe, can be used to obtain inhibitors of neurogenic vasodilatation, a significant progress in migraine and cancer treatments.
High Blood Pressure Linked To Fewer Headaches published
Tue, 15 Apr 2008 03:00:00 PDT
Researchers in Norway have shown that high blood pressure is linked to fewer headaches, possibly due to having stiffer artery walls which affects a homeostatic process that regulates blood pressure and decreases sensitivity to pain.
Taking Headache Seriously, UK published
Wed, 05 Mar 2008 03:00:00 PDT
A new survey conducted by Headache UK indicates that as many as 65% of migraine and headache sufferers have not found a satisfactory regime to manage their condition. And of those who responded to the survey, 28% feel that medical service providers around the UK are not at all well informed and well equipped to provide useful advice on the long term treatment of migraine and headaches.
Drug Doesn't Help Prevent Migraine After All published
Tue, 12 Feb 2008 01:00:00 PDT
Contrary to some reports, the epilepsy drug oxcarbazepine does not appear to prevent migraine, according to research published in the February 12, 2008, issue of Neurology®, the medical journal of the American Academy of Neurology.The nearly five-month study involved 170 men and women at clinics across the United States with half of the group receiving a daily dose of oxcarbazepine; the other half took placebo.
Discovery Of Link Between Human And Insect Reactions To Stress Means Comatose Locusts May Help Relieve Migraines published
Fri, 08 Feb 2008 04:00:00 PDT
The way locusts react to stress may provide an important clue to understanding what causes human migraines - and how to reduce their painful effects, says Queen's University Biology professor Mel Robertson.With PhD student Corinne Rodgers, Dr. Robertson is using insect models to examine how the nervous system controls breathing when stress is induced through high temperatures and oxygen deprivation.
NMT Medical Announces Significant Changes To Its Clinical Trial Plans In The United States published
Fri, 25 Jan 2008 05:00:00 PDT
NMT Medical, Inc. (NASDAQ: NMTI) nnounced that the Company is closing down its patent foramen ovale (PFO)/migraine trial, MIST II, to focus its resources on its PFO/stroke opportunity. The move is expected to save the Company approximately $14 million over the next two to three years as it redistributes investments originally budgeted for MIST II. As a result of this decision, NMT has ceased patient enrollment in MIST II, which was being conducted at 20 centers in the United States.
Mobile Effect On Sleep, NHS Choices Response published
Tue, 22 Jan 2008 01:00:00 PDT
"Radiation from mobile phones delays and reduces sleep, and causes headaches and confusion, according to a new study", reported The Independent on Sunday on January 20 2008. The Daily Telegraph also covered the story, reporting that a study funded by handset manufacturers found that using a mobile before going to bed could damage your health. The main health risk listed by the newspapers is less time in the deeper stages of sleep that can help the body recuperate.
POZEN Submits Human Lymphocyte Study For Treximet™ (Formerly Known As Trexima™) published
Thu, 17 Jan 2008 02:00:00 PDT
POZEN Inc. (NASDAQ: POZN) announced that it has submitted the findings from the short-term human volunteer study of the genotoxic potential of Treximet™ (formerly known as Trexima™) to the U.S. Food and Drug Administration (FDA).
MAP Pharmaceuticals Reaches Agreement With FDA On Special Protocol Assessment For MAP0004 Phase 3 Clinical Trial In Patients With Migraine published
Thu, 17 Jan 2008 00:00:00 PDT
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, announced that it has completed the special protocol assessment (SPA) process with the U.S. Food and Drug Administration (FDA) for the first Phase 3 clinical trial of its MAP0004 product candidate, and has reached agreement with the Agency on the design of the protocol. The study, if successful, could support the potential approval of MAP0004 as a treatment for migraine.
Newly Formed Council Issues Statement On Healthcare Provider Gaps Related To Education And Management Of Fibromyalgia Syndrome published
Mon, 31 Dec 2007 00:00:00 PDT
The newly formed Advisory Council on Fibromyalgia Education (ACFE) comprised of internationally recognized clinicians and researchers and developed to identify and provide solutions to educational gaps and barriers in the area of fibromyalgia syndrome issued a statement stating that several significant gaps exist in the identification, diagnosis and management of fibromyalgia patients.
Alexza Completes Target Enrollment In AZ-104 Phase 2a Clinical Trial In Migraine Patients published
Wed, 19 Dec 2007 00:00:00 PDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has completed its target patient enrollment in its Phase 2a proof-of-concept clinical trial with AZ-104 (Staccato(R) loxapine) in patients with migraine headache. AZ-104 is a lower dose version of AZ-004, which is being developed to treat acute agitation in patients with schizophrenia or bipolar disorder.
ProEthic Pharmaceuticals Announces Acceptance Of New Drug Application For Migraine published
Fri, 14 Dec 2007 01:00:00 PDT
ProEthic Pharmaceuticals, Inc., a privately funded specialty pharmaceutical company that acquires, develops, licenses and markets niche prescription products, announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's submission of its New Drug Application for PRO-513 for the treatment of migraine headaches. In accordance with the Prescription Drug User Fee Act (PDUFA), the FDA has set the goal date for their review as July 27, 2008.
New Study Published In The Lancet Neurology Shows Topamax(R) Provides Sustained Reduction In Monthly Migraine Days For Up To One Year published
Tue, 04 Dec 2007 02:00:00 PDT
A new long-term study into migraine prevention published in The Lancet Neurology shows that patients who continued with Topamax(R) (topiramate) for migraine prophylaxis for up to a year experienced a sustained reduction in the number of migraine days per month, with significant associated benefits on quality of life measures.
Genetic Testing May Help People With Severe Type Of Migraine published
Tue, 04 Dec 2007 00:00:00 PDT
People with a severe type of migraine in which one side of the body becomes weak should consider genetic testing, according to research that has found familial genes for this type of migraine in people who did not have family members experiencing the problem. The findings are published in the December 4, 2007, issue of Neurology®, the medical journal of the American Academy of Neurology.
Migraine Sufferers Have Thicker Brain Cortex published
Tue, 20 Nov 2007 03:00:00 PDT
A US study has found that the cortex area of the brain is thicker in people who have migraines compared to those who do not. The researchers do not know whether the difference causes the migraine or having migraine over the years has led to the difference in brain structure.
)
|
|
